Canadian COVID-19 host genetics cohort replicates known severity associations

PLoS Genet. 2024 Mar 22;20(3):e1011192. doi: 10.1371/journal.pgen.1011192. eCollection 2024 Mar.

Abstract

The HostSeq initiative recruited 10,059 Canadians infected with SARS-CoV-2 between March 2020 and March 2023, obtained clinical information on their disease experience and whole genome sequenced (WGS) their DNA. We analyzed the WGS data for genetic contributors to severe COVID-19 (considering 3,499 hospitalized cases and 4,975 non-hospitalized after quality control). We investigated the evidence for replication of loci reported by the International Host Genetics Initiative (HGI); analyzed the X chromosome; conducted rare variant gene-based analysis and polygenic risk score testing. Population stratification was adjusted for using meta-analysis across ancestry groups. We replicated two loci identified by the HGI for COVID-19 severity: the LZTFL1/SLC6A20 locus on chromosome 3 and the FOXP4 locus on chromosome 6 (the latter with a variant significant at P < 5E-8). We found novel significant associations with MRAS and WDR89 in gene-based analyses, and constructed a polygenic risk score that explained 1.01% of the variance in severe COVID-19. This study provides independent evidence confirming the robustness of previously identified COVID-19 severity loci by the HGI and identifies novel genes for further investigation.

Publication types

  • Meta-Analysis

MeSH terms

  • COVID-19* / genetics
  • Canada / epidemiology
  • Forkhead Transcription Factors
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Membrane Transport Proteins
  • North American People*
  • Polymorphism, Single Nucleotide
  • SARS-CoV-2 / genetics

Substances

  • SLC6A20 protein, human
  • Membrane Transport Proteins
  • FOXP4 protein, human
  • Forkhead Transcription Factors

Supplementary concepts

  • Canadian people

Grants and funding

ADP and LS were supported by Canadian Institutes of Health Research Project Grant 470360 (https://cihr-irsc.gc.ca). LJS was supported by Canadian Institutes of Health Research Foundation Grant 167282 (https://cihr-irsc.gc.ca) and Canada Research Chairs (https://www.chairs-chaires.gc.ca/). JL-E was supported by Canadian Institutes of Health Research Foundation Grant VR4-172753 (https://cihr-irsc.gc.ca). LTE was supported by Michael Smith Health Research BC Scholar Award SCH-2022-2784 (https://healthresearchbc.ca). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.